Puma Biotechnology Inc (NASDAQ:PBYI) has a beta value of 1.09 and has seen 0.63 million shares traded in the recent trading session. The company, currently valued at $191.31M, closed the recent trade at $3.90 per share which meant it gained $0.35 on the day or 9.78% during that session. The PBYI stock price is -98.21% off its 52-week high price of $7.73 and 43.08% above the 52-week low of $2.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.88 million shares traded. The 3-month trading volume is 490.40K shares.
The consensus among analysts is that Puma Biotechnology Inc (PBYI) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.14.
Puma Biotechnology Inc (NASDAQ:PBYI) trade information
Sporting 9.78% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PBYI stock price touched $3.90 or saw a rise of 3.94%. Year-to-date, Puma Biotechnology Inc shares have moved 27.78%, while the 5-day performance has seen it change 24.51%. Over the past 30 days, the shares of Puma Biotechnology Inc (NASDAQ:PBYI) have changed 26.95%. Short interest in the company has seen 2.91 million shares shorted with days to cover at 5.73.
Puma Biotechnology Inc (PBYI) estimates and forecasts
Figures show that Puma Biotechnology Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 28.20% over the past 6 months, with this year growth rate of -26.87%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be -4.97%.
2 analysts offering their estimates for the company have set an average revenue estimate of 52.5M for the current quarter. 1 have an estimated revenue figure of 47.5M for the next ending quarter. Year-ago sales stood 72.2M and 43.77M respectively for this quarter and the next, and analysts expect sales will shrink by -27.29% for the current quarter and -4.97% for the next.
PBYI Dividends
Puma Biotechnology Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Puma Biotechnology Inc (NASDAQ:PBYI)’s Major holders
Insiders own 15.02% of the company shares, while shares held by institutions stand at 67.74% with a share float percentage of 79.70%. Investors are also buoyed by the number of investors in a company, with Puma Biotechnology Inc having a total of 138.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 3.6 million shares worth more than $11.73 million. As of 2024-06-30, VANGUARD GROUP INC held 7.4684% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 3.57 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.65 million and represent 7.4141% of shares outstanding.
